Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. - Wikidata - awgldk - TriplyDB

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

http://www.wikidata.org/entity/Q47826637

about

Multi-Institutional Competing Risks Analysis of Distant Brain Failure and Salvage Patterns after Upfront Radiosurgery without Whole Brain Radiotherapy for Brain Metastasis.Designing In and Around Tolerability Considerations for Immunotherapy Combinations.Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Control of NK Cell Activation by Immune Checkpoint Molecules.Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.Immune Checkpoint Inhibitors in Melanoma and HIV Infection.The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors.Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.B cells as biomarkers: predicting immune checkpoint therapy adverse events.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.Immune checkpoint inhibitors: new strategies to checkmate cancer.Liquid biomarkers in melanoma: detection and discovery.The role of nivolumab in melanoma.Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.Current and future immunotherapies for thyroid cancer.Small-cell lung cancer in the era of immunotherapy.Melanoma in 2017: Moving treatments earlier to move further forwards.The Role of the Estrogen Pathway in the Tumor Microenvironment.Cancer immunotherapy: The dark side of PD-1 receptor inhibition.Impact of genomics on the surgical management of melanoma.Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.Treatment of uveal melanoma: where are we now?Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management.Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.Cutaneous melanoma: From pathogenesis to therapy (Review).When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Mechanisms of Resistance to PD-1 and PD-L1 Blockade.PD-L1 expression in medulloblastoma: an evaluation by subgroup.ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.A Convergence-Based Framework for Cancer Drug Resistance.Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.

P2860

Q46175985-73F3ADCC-1CA3-4E12-9076-AE7B6F766BC5 Q46252211-CFA6F9CA-1B0F-45CD-AF16-889D2C20BF0D Q46865924-B1BB9524-3790-4D4B-89EA-D44DCFD0EE9D Q47120629-8E2852C8-C51A-4A54-89ED-08867DD53938 Q47128718-1D5BBC16-CAEA-465D-97E4-A7998E0D37E5 Q47131425-F8F6FAB2-C38F-4F5E-B3F5-6E6C969D683C Q47132242-EEB0089D-0EE8-4CFD-89AC-0CAC7222CF7C Q47138765-EFE708F1-F3BA-4438-BDDA-458566AA8CB2 Q47154926-C0F3239E-A201-402C-9EB7-116B3466B79D Q47157402-4EB6ECE2-6CE8-44DB-8616-559484FC6015 Q47225274-46DAF0CD-D501-466E-8E81-24D54D31B6F3 Q47227422-4B6A63BF-4BE6-451D-A8B9-B7114A8BF2B4 Q47301132-49796085-3211-4511-B0C1-04A8011C82C4 Q47375181-E4D2A829-A7FC-43C3-8546-CCD406DA0A37 Q47400647-2CE673AB-A689-4897-BE5F-70B23AF394F4 Q47726847-8C453B65-2352-4FFD-B52D-7B7F55F639D0 Q47735641-47BEBF38-16B5-4D62-AD85-BECECBFA3055 Q47777833-5739D65C-FEF6-4DFB-9724-0A18C18390AD Q47781457-C1074237-B907-4C6F-940F-582EE5152814 Q49333151-5B84F878-8AF7-4414-A563-AE3A33D74555 Q49577605-FF02CD8C-1677-467E-89E3-FAD120854432 Q49803828-2024B6EB-FBB3-45F2-8220-8E944681BDAF Q49971148-C07C0814-150A-4160-81FF-5F7F9FDA12C0 Q50010320-289D91F7-18F6-4A29-91FB-F2420F8754A8 Q50125923-A843E799-F5FA-4CAC-943E-5949314FBDFA Q50349181-286A9A37-0F99-49BD-8DCB-7C61082C893E Q51743770-BF709609-403A-4057-8DA6-9370AC83FDFF Q52587406-C7C8EE11-B6FA-4870-80CF-F4039EFE3F9A Q52611551-2650772B-07D3-4308-988B-31DC93D5326B Q52649470-5E615CB7-0A22-4C18-AE04-61D0F2DD0BAA Q52654643-842BD563-B6C7-4218-81D0-11A954DC6866 Q52658584-5FC71489-5751-400D-AC21-15ED89D0A89D Q52689973-58504786-32A9-46C6-AE82-859841C2342A Q52707883-E36EB59F-DFBE-49C1-8897-CD748DA6E88E Q52714354-8779FE97-D564-44FB-840A-C4D8B0A488F6 Q52720857-D2BC16A1-EB98-4EF7-B190-23498F74EEAF Q52801913-3264B0B8-47C2-4EEF-8C31-D84BDFD6E422 Q53682041-C88F6587-A070-4236-B1DD-D59D5E55B25E Q54202082-3DC07AFB-C9EC-4948-BE71-FD61755EDA2C Q54215187-6A3326A6-DDAF-47D6-BB8E-B105767CF77C

P2860

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

http://www.wikidata.org/entity/Q47826637

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

@en

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

@nl

type

label

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

@en

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

@nl

prefLabel

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

@en

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

@nl

P1433

Q47826637-794F52B1-96A4-487C-B251-34922D5CA27A

P1476

Q47826637-0D00CBCF-654C-4296-9F7E-8EA269A36A42

P2093

Q47826637-02CA0344-F8D4-45E9-8C0E-24C22E57BBB8

Q47826637-07E1AC4C-3406-4F58-93B3-C34ED3C78175

Q47826637-0A3DF9E9-455C-4FAA-986F-1D4871F22B1E

Q47826637-118EC6F6-03BD-4A66-873E-819D9223CC83

Q47826637-1822C012-0965-41BB-90B8-7D1A69BF9C51

Q47826637-1DFEE390-C8D2-431E-8836-C9A7C8100D9A

Q47826637-2C2BD5CA-44CF-408B-B814-A9EC62BDFB9F

Q47826637-3D148B7B-DE0F-42E8-85DA-BACBC8C891EE

Q47826637-4C3F432A-E56A-4C43-A872-E6F61A5C2474

Q47826637-4D8030D1-F055-4A9C-9D4C-241415B17647

P2860

Q47826637-0F6D939C-5BF1-4622-90AF-E9AC0B81FD8E

Q47826637-5F2858BE-28C8-4DE2-A0D7-3B7CE55354F6

Q47826637-6FEB9FFE-0CCF-4083-BBC4-BEB6A3E00FB8

Q47826637-86085E38-F6AE-4A50-8F2C-240C51E9549A

Q47826637-A4D623F3-C1CD-496F-9238-27A93A1FB335

Q47826637-B13E2327-D93A-420C-A6FA-B6683943AA45

Q47826637-B8A90A95-267D-4C07-AB8C-8D6B7A9B4087

Q47826637-D81393B3-064C-4EA8-B937-6B9E1465B161

Q47826637-E16FF3EC-99E7-41E7-8400-09D170F6BEBC

Q47826637-EDC7ED94-AE36-4A2C-B223-BF391F9350EC

P304

Q47826637-64B1C26E-8CEF-4C40-A555-D12150C7A855

P31

Q47826637-E94833BE-7302-4F0A-9C62-E306F4490D3E

P356

Q47826637-A637DF60-2918-4F3D-8B5B-F920A6ACD260

P407

Q47826637-5E3D1E3B-BF96-40C0-BED6-BC0A4BCC0BC4

P433

Q47826637-4721BAEE-21D8-4397-A996-D9CE1A9BD0BF

P478

Q47826637-E13EC807-7363-415C-872E-3C4297EC4E2C

P50

Q47826637-3D8EC6C8-FC46-43A6-9A3F-134768486764

Q47826637-4CE5F588-39DB-48E4-A83F-30082A135B7F

Q47826637-5B2EF997-6028-42B6-A880-A6C9AC750D32

Q47826637-60822A5C-F979-4C71-9C80-FE1953F04352

Q47826637-7A2B640E-E57E-47CF-859F-98FD4FFFAB3E

Q47826637-C4FEB3C8-6D7E-4F41-9DA1-7A9C7AE13901

Q47826637-D593316B-776B-409C-8B6C-D797BD42336C

Q47826637-D7F4E952-F645-4EB8-B20A-1ECC1ACA3CFC

Q47826637-ECE0F589-D670-45E0-A0A3-1FA0C003AB96

P577

Q47826637-903822B9-4A36-4CFB-84DC-209BAAE53F31

P698

Q47826637-CD30236F-A708-4459-974D-3DE409C487EF

P932

Q47826637-FB3279A0-DC21-4015-BDC4-BE303AE5BDEB

P356

P1433

The New England Journal of Medicine

P1476

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

@en

P2093

Andrew Hill

http://www.w3.org/2001/XMLSchema#string

C Lance Cowey

http://www.w3.org/2001/XMLSchema#string

Celeste Lebbé

http://www.w3.org/2001/XMLSchema#string

Christopher D Lao

http://www.w3.org/2001/XMLSchema#string

Dana Walker

http://www.w3.org/2001/XMLSchema#string

David Hogg

http://www.w3.org/2001/XMLSchema#string

Dirk Schadendorf

http://www.w3.org/2001/XMLSchema#string

F Stephen Hodi

http://www.w3.org/2001/XMLSchema#string

James Larkin

http://www.w3.org/2001/XMLSchema#string

Jean-Jacques Grob

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Time-dependent ROC curves for censored survival data and a diagnostic marker.

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

P304

1345-1356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1709684

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

377

http://www.w3.org/2001/XMLSchema#string

P50

Pier Francesco Ferrucci

Georgina V. Long

Massimo Guidoboni

Piotr Rutkowski

I Marquez-Rodas

V Chiarion-Sileni

P577

2017-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28889792

http://www.w3.org/2001/XMLSchema#string

P932

5706778

http://www.w3.org/2001/XMLSchema#string